Osiris gets funding for three clinical trials

06/9/2005 | Sun (Baltimore), The

Baltimore-based Osiris Therapeutics said it obtained $50 million in new financing to fund three clinical trials of its potential adult stem cell therapy products, including a treatment for graft-versus-host disease that arises with some stem cell transplants. CEO Randal Mills said his firm could become the first to bring a stem cell therapy to the market.

View Full Article in:

Sun (Baltimore), The

Published in Brief:

SmartBrief Job Listings for Health Care

Job Title Company Location
Counsel – Regulatory Affairs
RAI Services Company
Winston Salem, NC
Director of Program Development
AdvaMed
Washington DC, DC
Director of System QA
LifeWatch Services, Inc.
Rosemont, IL
Director of Business Development and Membership
AdvaMed
Washington DC, DC
Director, Corporate Counsel
Regeneron
Tarrytown, NY